Department of Thoracic Oncology, Institute for Clinical Research, National Kyushu Cancer Center, Minami-ku, Fukuoka, Japan.
Anticancer Res. 2010 Apr;30(4):1311-5.
To analyse the prognostic factors for patients with non-small cell lung cancer (NSCLC) who underwent cytotoxic chemotherapy with third generation agents or epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for recurrence.
Between 1997 and 2005, 479 patients underwent a complete resection for NSCLC. Of these, 112 patients underwent chemotherapy for postoperative recurrence.
Median postrecurrence survival time for these 112 patients was 25.6 months. Univariate analysis showed female gender, age younger than 65 years, ECOG performance status of 0-1, never-smoker status, and adenocarcinoma prolonged survival, whereas metastasis to the liver or adrenal gland shortened survival. Multivariate analysis revealed age, performance status, cell type and metastasis to the adrenal gland to be independent prognostic factors.
Age, performance status, cell type, and metastasis to the adrenal were independent prognostic factors in NSCLC patients treated with third-generation agents or EGFR-TKI for recurrence.
分析接受第三代药物或表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)进行细胞毒性化疗治疗复发性非小细胞肺癌(NSCLC)患者的预后因素。
1997 年至 2005 年间,479 例 NSCLC 患者接受了完全切除术。其中,112 例患者因术后复发而接受化疗。
112 例患者的中位复发后生存时间为 25.6 个月。单因素分析显示,女性、年龄小于 65 岁、ECOG 表现状态为 0-1、从不吸烟状态和腺癌延长了生存时间,而肝或肾上腺转移则缩短了生存时间。多因素分析显示,年龄、表现状态、细胞类型和肾上腺转移是独立的预后因素。
在接受第三代药物或 EGFR-TKI 治疗复发性 NSCLC 患者中,年龄、表现状态、细胞类型和肾上腺转移是独立的预后因素。